首页> 外文OA文献 >A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study

【2h】

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study

机译：在Her2-阳性局部晚期/转移性乳腺癌患者中，Hertuzumab患者的随机开放标签，腹部疗法试验，先前用Pertuzumab，Trastuzumab和化疗治疗：日本乳腺癌研究组-M05珍贵研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Yutaka Yamamoto; Hiroji Iwata; Takayuki Ueno; Naruto Taira; Masahiro Kashiwaba; Masato Takahashi; Hiroshi Tada; Koichiro Tsugawa; Tatsuya Toyama; Naoki Niikura; Fumikata Hara; Tomomi Fujisawa; Tetsuhiro Yoshinami; Shigehira Saji; Toshimi Takano; Norikazu Masuda; Satoshi Morita; Masakazu Toi; Shinji Ohno;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study [J] . Yamamoto Yutaka, Iwata Hiroji, Ueno Takayuki, Japanese journal of clinical oncology. . 2018,第9期

机译：在Her2阳性局部晚期/转移性乳腺癌患者中，Hertuzumab患者的随机开放标签，腹部疗法试验，曲妥珠单抗和化疗：日本乳腺癌研究组-M05珍贵研究
2. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [J] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, Trials . 2020,第1期

机译：Trastuzumab，Pertuzumab和Eribulin甲磺酸丁酯与曲妥珠单抗，Pertuzumab和紫罗兰作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势，III期的研究方案日本试验（JBCRG-M06 / Emerald）
3. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group [J] . Wildiers Hans, Tryfonidis Konstantinos, Dal Lago Lissandra, The lancet oncology . 2018,第3期

机译：Pertuzumab和Trastuzumab有或没有用于老年人阳性转移性乳腺癌患者的沟通化疗（EORTC 75111-10114）：从老年人任务/乳腺癌组的开放标签，随机，第2阶段试验
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：曲妥珠单抗帕妥珠单抗和甲磺酸艾瑞布林与曲妥珠单抗帕妥珠单抗和紫杉烷作为一线或二线治疗HER2阳性局部晚期或转移性乳腺癌的一线或二线治疗：III期随机对照非劣效性的研究方案在日本试用（JBCRG-M06 / EMERALD）
7. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：Trastuzumab，Pertuzumab和Eribulin甲蛋白与曲妥珠单抗，Pertuzumab和紫杉烷作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势的研究方案，日本第三阶段试验（JBCRG-M06 / Emerald）

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study

著录项

相似文献

相关主题

期刊订阅